-
May 16, 2024
Poster – ASGCT 2024 – A Fully Integrated and Highly Sensitive Approach to Predicting and Measuring Off-Target Variation in CRISPR Edited Gene Therapy Products
From discovery to the post clinical market, we provide assays, datasets and reports to facilitate every stage of the gene therapy development pipeline
-
May 16, 2024
Poster – ASGCT 2024 – SAFER-Detection for Efficient Interrogation of DNA Rearrangements in Gene-edited Human Cells
Our SAFER Detection assay identifies intra-chromosomal and inter-chromosomal rearrangements events with high sensitivity in Cas9-edited samples from low cell counts.
-
May 16, 2024
Poster – ASGCT 2024 – ONE-seq for Variant-Aware Therapeutic Guide Selection
Learn about the latest improvements we’ve made to the ONE-seq assay, including the use case of screening multiple (6-12) guides at once, or in depth 3 guide comparisons
-
December 08, 2022
One Genome or Thousands of Genomes? Population genomics and off-target risks
SeQure Dx CSO Tom Mullen, PhD discusses population genomics and off-target risks of gene-editing therapies